Management of Untreated and Nonresponder Patients with Chronic Hepatitis C

ABSTRACT

Hepatitis C infection has evolved in the past quarter century from a newly recognized entity without a known pathogen (non-A, non-B hepatitis) to one of the world's most prevalent causes of liver disease, an important source for hepatocellular carcinoma, and the major indication for liver transplantation. It is caused by a virus with a complex replication cycle that occurs in multiple genotypes, of which the four most prevalent (1, 2, 3, and 4) exhibit differences in clinical behavior and responses to therapy. Chronic hepatitis C virus (HCV) in particular has evolved from a disease with no known treatment to one with several primary treatment options, none of which is uniformly effective, and a growing list of secondary treatment options for those who have failed to respond to, or relapsed after initial therapy. As treatment is often associated with significant side effects, it is now a disease that presents clinicians with multiple important decisions: whom to treat, when and with what to treat them initially, and how to manage patients who have failed during initial therapy to achieve a sustained virological response, the gold standard of effective therapy. This review examines each of these important decisions, presenting evidence to help guide clinicians in their choices. The decisions are addressed sequentially as they arise during the initial evaluation and subsequent treatment of a typical, newly recognized patient with chronic HCV, and the considerations facing the clinician when the patient has failed to achieve an SVR.

KEYWORDS

Chronic hepatitis C - peginterferon - ribavirin - sustained virologic response - nonresponder - retreatment

REFERENCES

• 1 Ghany M G, Strader D B, Thomas D L, Seeff L B. American Association for the Study of Liver Diseases . Diagnosis, management, and treatment of hepatitis C: an update.  Hepatology. 2009;  49(4) 1335-1374
• 2 Pawlotsky J M, Lonjon I, Hezode C et al.. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?.  Hepatology. 1998;  27(6) 1700-1702
• 3 Harris D R, Gonin R, Alter H J National Heart, Lung, and Blood Institute Study Group et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse.  Ann Intern Med. 2001;  134(2) 120-124
• 4 Noda K, Yoshihara H, Suzuki K et al.. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma—its relationship to alcohol drinking and the age of transfusion.  Alcohol Clin Exp Res. 1996;  20(1, Suppl) 95A-100A
• 5 Romero-Gómez M, Grande L, Nogales M C, Fernández M, Chavez M, Castro M. Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption.  Dig Liver Dis. 2001;  33(8) 698-702
• 6 Pessione F, Degos F, Marcellin P et al.. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.  Hepatology. 1998;  27(6) 1717-1722
• 7 Westin J, Lagging L M, Spak F et al.. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection.  J Viral Hepat. 2002;  9(3) 235-241
• 8 Seeff L B, Curto T M, Szabo G HALT-C Trial Group et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.  Hepatology. 2008;  47(2) 605-612
• 9 Seeff L B, Lindsay K L, Bacon B R, Kresina T F, Hoofnagle J H. Complementary and alternative medicine in chronic liver disease.  Hepatology. 2001;  34(3) 595-603
• 10 Modi A A, Wright E C, Seeff L B. Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review.  Antivir Ther. 2007;  12(3) 285-295
• 11 Ferenci P, Scherzer T M, Kerschner H et al.. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.  Gastroenterology. 2008;  135(5) 1561-1567
• 12 Wagoner J, Negash A, Kane O J et al.. Multiple effects of silymarin on the hepatitis C virus lifecycle.  Hepatology. 2010;  51(6) 1912-1921
• 13 Seeff L B. Are herbals as safe as their advocates believe?.  J Hepatol. 2009;  50(1) 13-16
• 14 Vento S, Garofano T, Renzini C et al.. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.  N Engl J Med. 1998;  338(5) 286-290
• 15 Tsai J F, Jeng J E, Ho M S, Chang W Y, Lin Z Y, Tsai J H. Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis.  J Hepatol. 1996;  24(3) 271-276
• 16 Alter M J. Prevention of spread of hepatitis C.  Hepatology. 2002;  36(5, Suppl 1) S93-S98
• 17 Thomas D L, Seeff L B. Natural history of hepatitis C.  Clin Liver Dis. 2005;  9(3) 383-398, vi vi
• 18 Seeff L B. The history of the “natural history” of hepatitis C (1968-2009).  Liver Int. 2009;  29(Suppl 1) 89-99
• 19 Verna E C, Lefkowitch J H, Berk P D. Chronic hepatitis C of 28 years' duration characterized by early development of stage 2 (of 4) fibrosis but no significant progression over the subsequent 18 years.  Semin Liver Dis. 2010;  30(3) 302-309
• 20 Kleiner D E. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope.  Semin Liver Dis. 2005;  25(1) 52-64
• 21 Bedossa P, Poynard T. The METAVIR Cooperative Study Group . An algorithm for the grading of activity in chronic hepatitis C.  Hepatology. 1996;  24(2) 289-293
• 22 Batts K P, Ludwig J. Chronic hepatitis. An update on terminology and reporting.  Am J Surg Pathol. 1995;  19(12) 1409-1417
• 23 Desmet V J, Gerber M, Hoofnagle J H, Manns M, Scheuer P J. Classification of chronic hepatitis: diagnosis, grading and staging.  Hepatology. 1994;  19(6) 1513-1520
• 24 Ishak K, Baptista A, Bianchi L et al.. Histological grading and staging of chronic hepatitis.  J Hepatol. 1995;  22(6) 696-699
• 25 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358(9286) 958-965
• 26 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347(13) 975-982
• 27 Hadziyannis S J, Sette Jr H, Morgan T R PEGASYS International Study Group et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.  Ann Intern Med. 2004;  140(5) 346-355
• 28 Pradat P, Tillmann H L, Sauleda S HENCORE Group et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.  J Viral Hepat. 2007;  14(8) 556-563
• 29 Bruno S, Crosignani A, Facciotto C et al.. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.  Hepatology. 2010;  51(6) 2069-2076
• 30 Bruno S, Stroffolini T, Colombo M Italian Association of the Study of the Liver Disease (AISF) et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.  Hepatology. 2007;  45(3) 579-587
• 31 Veldt B J, Heathcote E J, Wedemeyer H et al.. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.  Ann Intern Med. 2007;  147(10) 677-684
• 32 Morgan T R, Ghany M G, Kim H Y et al.. Outcome of sustained virological responders with histologically advanced chronic hepatitis C.  Hepatology. 2010;  52(3) 833-844
• 33 Davis G L, Wong J B, McHutchison J G, Manns M P, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.  Hepatology. 2003;  38(3) 645-652
• 34 Ge D, Fellay J, Thompson A J et al.. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.  Nature. 2009;  461(7262) 399-401
• 35 Suppiah V, Moldovan M, Ahlenstiel G et al.. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.  Nat Genet. 2009;  41(10) 1100-1104
• 36 Tanaka Y, Nishida N, Sugiyama M et al.. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.  Nat Genet. 2009;  41(10) 1105-1109
• 37 Rauch A, Kutalik Z, Descombes P et al.. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.  Gastroenterology. 2010;  138(4) 1338-1345, 1345 e1–7
• 38 McCarthy J J, Li J H, Thompson A et al.. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.  Gastroenterology. 2010;  138(7) 2307-2314
• 39 Afdhal N H, Dieterich D T, Pockros P J Proactive Study Group et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.  Gastroenterology. 2004;  126(5) 1302-1311
• 40 Pockros P J, Shiffman M L, Schiff E R PROACTIVE Study Group et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.  Hepatology. 2004;  40(6) 1450-1458
• 41 Del Rio R A, Post A B, Singer M E. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.  Hepatology. 2006;  44(6) 1598-1606
• 42 Bennett C L, Silver S M, Djulbegovic B et al.. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.  JAMA. 2008;  299(8) 914-924
• 43 McHutchison J G, Dusheiko G, Shiffman M L TPL102357 Study Group et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.  N Engl J Med. 2007;  357(22) 2227-2236
• 44 Mac Nicholas R, Norris S. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV – the role of epoetin, G-CSF and novel agents.  Aliment Pharmacol Ther. 2010;  31(9) 929-937
• 45 Poynard T, Colombo M, Bruix J et al.. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.  Gastroenterology. 2009;  136(5) 1618-1628 e2.
• 46 Fattovich G, Giustina G, Degos F et al.. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.  Gastroenterology. 1997;  112(2) 463-472
• 47 Jensen D M, Marcellin P, Freilich B et al.. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.  Ann Intern Med. 2009;  150(8) 528-540
• 48 Bacon B R, Shiffman M L, Mendes F et al.. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.  Hepatology. 2009;  49(6) 1838-1846
• 49 Witthöft T. Review of consensus interferon in the treatment of chronic hepatitis C.  Biologics. 2008;  2(4) 635-643
• 50 Nelson D R, Rustgi V, Balan V et al.. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.  Clin Gastroenterol Hepatol. 2009;  7(2) 212-218
• 51 Di Bisceglie A M, Shiffman M L, Everson G T HALT-C Trial Investigators et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.  N Engl J Med. 2008;  359(23) 2429-2441
• 52 Afdhal N HLR, Brown R S, Freilich B, O'Brien M, Bass C. Colchicine versus PEG-interferon alfa-2b long term therapy: results of the 4-year COPILOT trial.  J Hepatol. 2008;  48 S4
• 53 Bruix J, Poynard T, Colombo M et al.. PEGINTRON maintenance therapy in cirrhotic (Metavir F4) HCV patients who failed to respond to interferon/ribavirin (IR) therapy: final results of the EPIC3 Cirrhosis Maintenance Trial.  J Hepatol. 2009;  50(Suppl 1) S22
• 54 Shiffman M L, Hofmann C M, Contos M J et al.. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.  Gastroenterology. 1999;  117(5) 1164-1172
• 55 Imai Y, Kawata S, Tamura S Osaka Hepatocellular Carcinoma Prevention Study Group et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C.  Ann Intern Med. 1998;  129(2) 94-99
• 56 Alric L, Duffaut M, Selves J et al.. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial.  J Hepatol. 2001;  35(2) 272-278
• 57 Hézode C, Forestier N, Dusheiko G PROVE2 Study Team et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.  N Engl J Med. 2009;  360(18) 1839-1850
• 58 Kwo P LE, Lawitz E, Schiff E et al.. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron/ribavirin in treatment naıšve subjects with genotype-1 chronic hepatitis C.  J Hepatol. 2009;  50(Suppl 1) S4
• 59 McHutchison J G, Manns M P, Muir A J et al.. Telaprevir for previously treated chronic HCV infection.  N Engl J Med. 2010;  362(14) 1292-1303
• 60 Kwo P Y, McCone J, Schiff E R, Vierling J M et al.. High sustained virologic response (SVR) in genotype 1 (G1) null responders to peg-interferon alfa-2b (P) plus ribavirin (R) when treated with boceprevir (Boc) combination therapy.  Hepatology. 2009;  50 331A–-332A
• 61 Rossignol J F, Kabil S M, El-Gohary Y, Elfert A, Keeffe E B. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.  Aliment Pharmacol Ther. 2008;  28(5) 574-580
• 62 Shiffman M L, Ahmed A, Jacobson I M, Pruitt R E, Keefe E B. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic hepatitis C genotype 1: final report.  J Hepatol. 2010;  52(Suppl 1) S461
• 63 Chow J, Liu Y, Comstock K et al.. Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor.  J Pharm Biomed Anal. 2010;  53(3) 710-716
• 64 Gane E J, Rodriguez-Torres M, Nelson D E et al. Sustained virologic response (SVR) following RG7128 1500 mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders.  J Hepatol. 2010;  52(Suppl 1) S16
• 65 Ferenci P, Fried M W, Shiffman M L et al.. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.  J Hepatol. 2005;  43(3) 425-433